SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
-9.51%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.44B
AUM Growth
+$1.44B
(-5%)
Cap. Flow
+$114M
Cap. Flow
% of AUM
7.93%
Top 10 Holdings %
Top 10 Hldgs %
59.95%
Holding
66
New
13
Increased
16
Reduced
8
Closed
9
Top Buys
| 1 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$53.7M |
| 2 |
Elanco Animal Health
ELAN
|
$40.6M |
| 3 |
Sanofi
SNY
|
$37.3M |
| 4 |
Kenvue
KVUE
|
$36.2M |
| 5 |
Merck
MRK
|
$20.7M |
Top Sells
| 1 |
Vertex Pharmaceuticals
VRTX
|
$51.1M |
| 2 |
Exelixis
EXEL
|
$37.8M |
| 3 |
Boston Scientific
BSX
|
$32.9M |
| 4 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$32.9M |
| 5 |
AstraZeneca
AZN
|
$22.7M |
Sector Composition
| 1 | Healthcare | 94.38% |
| 2 | Consumer Staples | 2.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $234M | 14.73% | 1,381,149 | – | – |
|
2
Natera
NTRA
$23.1B
| $137M | 8.65% | 3,100,560 | – | – |
|
|
3
AstraZeneca
AZN
$248B
| $92.3M | 5.82% | 1,362,836 -334,681 | -20% | -$22.7M |
|
|
4
Merck
MRK
$210B
| $75M | 4.73% | 728,404 +201,031 | +38% | +$20.7M |
|
5
Ascendis Pharma
ASND
$11.8B
| $70.6M | 4.45% | 754,032 | – | – |
|
|
RYZB
6
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $53.7M | 3.39% | +2,419,528 | New | +$53.7M |
|
7
DexCom
DXCM
$29.5B
| $51.3M | 3.24% | 550,197 +179,477 | +48% | +$16.7M |
|
|
JBIO
8
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $51M | 3.22% | 3,758,686 | – | – |
|
9
Intuitive Surgical
ISRG
$170B
| $50.6M | 3.19% | 173,277 -27,905 | -14% | -$8.16M |
|
10
Vera Therapeutics
VERA
$1.38B
| $47.5M | 3% | 3,467,156 | – | – |
|
|
11
Elanco Animal Health
ELAN
$9.12B
| $40.6M | 2.56% | +3,610,024 | New | +$40.6M |
|
12
argenx
ARGX
$43.6B
| $38.4M | 2.42% | 78,186 +38,265 | +96% | +$18.8M |
|
13
Immatics
IMTX
$619M
| $37.7M | 2.38% | 3,251,509 +210,022 | +7% | +$2.43M |
|
|
14
Sanofi
SNY
$121B
| $37.3M | 2.35% | +695,375 | New | +$37.3M |
|
|
15
Kenvue
KVUE
$39.7B
| $36.2M | 2.28% | +1,802,084 | New | +$36.2M |
|
16
Idexx Laboratories
IDXX
$51.8B
| $34.1M | 2.15% | 77,881 +7,207 | +10% | +$3.15M |
|
|
IMGN
17
DELISTED
Immunogen Inc
IMGN
| $32.5M | 2.05% | 2,045,202 +1,217,884 | +147% | +$19.3M |
|
18
Cytokinetics
CYTK
$4.23B
| $31.2M | 1.97% | 1,060,164 +216,936 | +26% | +$6.39M |
|
19
IDEAYA Biosciences
IDYA
$2.15B
| $28M | 1.77% | 1,037,187 +372,441 | +56% | +$10M |
|
20
Zentalis Pharmaceuticals
ZNTL
$122M
| $24.3M | 1.53% | 1,211,641 +383,636 | +46% | +$7.7M |
|
|
21
Exelixis
EXEL
$10.1B
| $18.2M | 1.15% | 830,764 -1,729,974 | -68% | -$37.8M |
|
|
INZY
22
DELISTED
Inozyme Pharma
INZY
| $18M | 1.13% | 4,280,308 +625,000 | +17% | +$2.63M |
|
23
Invesco QQQ Trust
QQQ
$364B
| $17.9M | 1.13% | +50,000 | New | +$17.9M |
|
24
MoonLake Immunotherapeutics
MLTX
$3.54B
| $16.7M | 1.05% | +292,805 | New | +$16.7M |
|
|
AGEN
25
Agenus
AGEN
$133M
| $15.1M | 0.95% | 13,364,748 +8,455,616 | +172% | +$9.55M |
|